A REVIEW ON COVID-19-A GLOBAL BATTLE BETWEEN LIFE AND DEATH
Currently, the globe is affected by a severe pandemic scenario of COVID-19 infection. The Covid-19 infectious disease is spreading everywhere on the globe particularly in developed countries like China, u. s. Italy, France, Spain, Iran, England, Germany, South Korea, etc. a deadly disease of a unique coronavirus (COVID‐19 or 2019‐CoV) infection has exhibited significant threats to global health, and also the economy. Following an outbreak of pneumonia without a transparent cause within the city of Wuhan in China, a novel strain of coronavirus (2019-nCoV) was detected in December 2019. Coronavirus is called for the spikes that protrude from their membranes just like the sun's corona. In line with WHO, Common signs of infection embrace fever, cold, cough, and respiratory difficulties like dyspnea, pneumonia. Within the absence of treatment for this virus, there's an imperative got to notice various strategies to manage the unfold of disease. It's “Corona time,” however; unfortunately, it's the virus that we tend to speak. In this paper, the origin of the viral infection, the clinical characteristics of Covid-19, etiology, pathogenesis, symptoms treatment and hindrance of Covid-19 are comprehensively detailed. At the time of this writing there are more queries than answers. The aim of our article is to provide a comprehensive understanding of COVID-19 to the peoples, so they'll better understand it and prevent it.
2. Chan JF, Lau SK, To KK. Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin Microbiol Rev 2015;28:465.
3. http://ictvonline.org/virusTaxonomy.asp [Last accessed on 02 Mar 2015]
4. Bonilla PJ, Gorbalenya AE, Weiss SR. Mouse hepatitis virus strain A59 RNA polymerase gene ORF 1a: heterogeneity among MHV strains. Virology 1994;198:736–40.
5. Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R. Coronavirus main proteinase (3CLpro) structure: basis for the design of anti-SARS drugs. Science 2003;300:1763–7.
6. Commentary: McIntosh K, Chao RK, Krause HE, Wasil R, Mocega HE, Mufson MA. Coronavirus infection in acute lower respiratory tract disease of infants. J Infect Dis 2004;190:1033–5.
7. Masters PS, Perlman S. Coronaviridae. In: Fields Virology. 6th ed. Knipe DM, Howley PM, Cohen JI. et al. (Eds). Vol. 2. Lippincott Williams and Wilkins, a Wolters Kluwer business, Philadelphia; 2013. p. 825.
8. https://www.nih.gov/news-events/nih-research-matters/novel-coronavirus-structure-reveals-targets-vaccines-treatments [Last accessed on 03 Mar 2020]
9. Adnan Shereen M, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: origin, transmission, and characteristics of human coronaviruses. J Adv Res 2020;1:25.
10. Perlman S, Netland J. Coronaviruses post-SARS: update on replication and pathogenesis. Nat Rev Microbiol 2009;7:439-50.
11. Li Q, Guan X, Wu P, Wang X. Early transmission dynamics in wuhan, china, of novel coronavirus-infected pneumonia. N Engl J Med 2020;382:1199-207.
12. https://english.jagran.com/india/coronavirus-outbreak-india-in-stage-2-of-covid19-transmission-a-look-at-four-stages-of-virus-spread-10009781 [Last accessed on 21 Mar 2020]
13. https://www.mayoclinic.org/diseases-conditions/ coronavirus/diagnosis-treatment/drc-20479976 [Last accessed on 20 Dec 2019]
14. Keyaerts E, Vijgen L, Maes P. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun 2004;323:264.
15. Kono M, Tatsumi K, Imai AM. Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: involvement of p38 MAPK and ERK. Antiviral Res 2008;77:150.
16. Keyaerts E, Li S, Vijgen L. Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice. Antimicrob Agents Chemother 2009;53:3416.
17. Otter JA, Donskey C, Yezli S. Transmission of SARS and MERS coronaviruses and influenza virus in healthcare settings: the possible role of dry surface contamination. J Hosp Infect 2016;92:235.
18. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/infection-prevention-and-control [Last accessed on 19 Mar 2020]
This work is licensed under a Creative Commons Attribution 4.0 International License.